PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
A multiple myeloma diagnosis usually produces an immediate focus on one question:
How do I treat the cancer?
But there is another question that deserves equal attention:
What side effects can multiple myeloma—and its treatment—cause, and what can I do about them?
Multiple myeloma is a complicated blood cancer. Some problems are caused by the disease itself. Others are caused by chemotherapy, targeted drugs, steroids, radiation, stem cell transplantation, or supportive medications.
And some side effects disappear when treatment ends. Others can persist for months or years.
For patients and caregivers, learning to recognize, report, prevent, and manage these problems is an important part of living well with multiple myeloma.
I am a long-term multiple myeloma survivor. My own experience taught me that surviving the cancer and managing the consequences of treatment are two different challenges.
My research and experience with evidence-based non-conventional therapies is the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage multiple myeloma is to combine the best of conventional and evidence-based non-conventional therapies.
I have come to believe that therapy-induced side effects can be life-threatening while ruining quality of life. Consider therapies shown to reduce possible side effects.
This guide brings together some of the most important multiple myeloma side-effect resources on PeopleBeatingCancer.
Important: This article is educational information, not a substitute for medical care. Tell your hematologist/oncologist about new, worsening, or severe symptoms. Some complications of multiple myeloma require urgent treatment.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about multiple myeloma.
Good luck,
It helps to divide myeloma-related problems into two broad categories:
The disease can:
The National Cancer Institute notes that myeloma can weaken bones, reduce production of normal blood cells and cause hypercalcemia, kidney problems and neurologic symptoms.
Myeloma therapies can cause problems involving:
The exact risks depend on the drugs and treatment combinations used.
For example, bortezomib can cause peripheral neuropathy, while lenalidomide can cause diarrhea and low blood counts. Carfilzomib can cause fatigue, gastrointestinal problems and, in some patients, serious heart or kidney complications.
That is why “multiple myeloma side effects” isn’t really one problem. It is a collection of problems that can occur at different points during the myeloma journey.
Peripheral neuropathy is one of the most important treatment-related complications of multiple myeloma.
Symptoms can include:
Certain myeloma treatments—notably bortezomib and thalidomide—can damage peripheral nerves.
Research has described peripheral neuropathy as one of the most important complications of myeloma treatment, with risk influenced by the particular drug, dose, schedule and combination of therapies.
This article examines approaches patients can discuss with their healthcare team for managing chemotherapy-induced peripheral neuropathy, including exercise, nutritional approaches, acupuncture and other complementary strategies.
Important: “Natural” or “home” remedies should not automatically be assumed to be safe or effective. Evidence varies considerably among these approaches, and some supplements can interact with cancer treatment. Always discuss supplements and complementary therapies with your oncology team.
This is one of the most important articles in this side-effect cluster because CIPN can become a long-term quality-of-life problem.
Early reporting matters. Don’t wait until numbness or pain becomes severe before telling your medical team.
Bone disease is one of the defining complications of multiple myeloma.
Myeloma cells can stimulate bone destruction, resulting in:
The American Cancer Society explains that myeloma can interfere with normal bone remodeling, weakening bones and increasing fracture risk.
Bone pain deserves particular attention because it can be caused by the disease itself, treatment-related damage, nerve damage or a combination of problems.
New or sudden severe back pain, numbness, weakness or difficulty walking can signal spinal cord compression and requires urgent medical evaluation.
Fatigue is one of the most common and frustrating problems experienced by people with multiple myeloma.
It can result from:
The National Cancer Institute notes that both cancer and cancer treatment can cause fatigue, and anemia is an important contributor.
Fatigue shouldn’t automatically be dismissed as something patients simply have to tolerate. Its cause should be investigated.
Some adverse effects occur during treatment and improve afterward.
Common examples include:
Multiple Myeloma Treatment Side Effects: 11 Common Short-Term Problems and How to Manage Them
This article is particularly useful as a starting point for newly diagnosed patients preparing for treatment.
The important distinction is that short-term does not necessarily mean harmless. Severe diarrhea, dehydration, infection, electrolyte abnormalities or dangerously low blood counts can require medical intervention.
Kidney problems can be caused by multiple myeloma itself as well as by certain treatments.
Myeloma proteins can damage the kidneys, and hypercalcemia can further impair kidney function.
Kidney function should therefore be monitored throughout the myeloma journey.
Patients should ask their medical team about their:
Kidney function can also influence which medications can safely be used.
Multiple myeloma can interfere with normal immune function, while treatment can suppress blood-cell production.
Problems can include:
The American Cancer Society notes that shortages of red cells, white cells and platelets can cause fatigue, infection risk and bleeding problems.
Fever or other signs of infection during active myeloma treatment should not be ignored.
Some myeloma treatments increase the risk of venous thromboembolism.
The risk can be influenced by:
Thalidomide and lenalidomide, for example, are associated with increased clotting risk.
Ask your hematologist whether your treatment regimen warrants preventive measures.
Cardiovascular complications deserve more attention as myeloma patients live longer.
Some myeloma therapies can affect cardiovascular function.
Potential problems include:
Some proteasome inhibitors and other cancer drugs have recognized cardiovascular risks. Carfilzomib, for example, can cause serious heart problems in some patients.
Patients with existing cardiovascular risk factors should discuss those risks before treatment begins.
Some cancer survivors experience persistent problems with:
PeopleBeatingCancer has several articles exploring cognitive problems after cancer treatment.
Cognitive symptoms can be influenced by much more than chemotherapy—including fatigue, sleep problems, medications, stress, pain and aging—so persistent symptoms deserve an appropriate medical evaluation.
Dexamethasone and other corticosteroids have an important role in many myeloma treatment regimens.
But steroids can produce significant side effects, particularly with prolonged or high-dose exposure.
Potential problems include:
Steroid doses should never be changed or stopped without discussing it with the prescribing physician.
Long-term steroid exposure can increase the risk of cataracts.
Some newer myeloma treatments can also produce important ocular toxicity.
For example, belantamab mafodotin can cause serious eye and corneal problems and requires specific eye monitoring.
GI problems are common during myeloma treatment.
They include:
The specific cause matters because treatment differs.
For example, constipation may be related to medications, dehydration or reduced activity, while diarrhea can result from particular myeloma drugs or other causes.
The American Cancer Society lists gastrointestinal problems among common adverse effects of several myeloma therapies.
Perhaps the most overlooked category is the side effect that appears months or years after treatment.
These can include:
A recent systematic review and meta-analysis involving nearly 280,000 people with multiple myeloma found that hematologic second primary malignancies were substantially more common than in the general population, emphasizing why long-term survivorship monitoring matters.
Side-effect management isn’t an optional extra.
A major review of supportive care in multiple myeloma identifies bone disease, thrombosis, infection risk, peripheral neuropathy, gastrointestinal and ocular toxicities and fatigue among the problems requiring active management.
In other words:
Treating the myeloma is only part of treating the patient.
Good supportive care can help patients:
Before beginning a new treatment, consider asking:
That last question is particularly important.
Patients and caregivers can keep a simple record of:
| Side effect | When did it begin? | Severity | Getting better or worse? | Reported to doctor? |
|---|---|---|---|---|
| Fatigue | ||||
| Nausea | ||||
| Diarrhea/constipation | ||||
| Neuropathy | ||||
| Pain | ||||
| Shortness of breath | ||||
| Swelling | ||||
| Vision changes | ||||
| Sleep problems | ||||
| Cognitive problems | ||||
| Mood changes | ||||
| Infection/fever |
Keeping a record can help you and your medical team recognize patterns and decide whether a medication, dose or treatment strategy needs to change.
Some symptoms require immediate medical attention.
Contact your medical team urgently—or seek emergency care when appropriate—for symptoms such as:
Spinal cord compression and hyperviscosity syndrome, for example, can be medical emergencies.
Multiple myeloma side effects are not limited to nausea and fatigue during chemotherapy.
The disease itself can cause bone damage, pain, anemia, kidney problems, hypercalcemia, infection and neurologic complications.
Treatment can add another layer of potential problems, including peripheral neuropathy, gastrointestinal symptoms, low blood counts, blood clots, cardiovascular toxicity, eye problems, cognitive changes and long-term organ damage.
The good news is that many side effects can be anticipated, monitored and treated.
The better patients understand the potential problems before they occur, the better prepared they are to recognize symptoms early and communicate effectively with their medical team.
For me, as a long-term myeloma survivor, this has become an important lesson:
Managing multiple myeloma means managing both the cancer and the consequences of treating the cancer.
I would use these as the core evidence links, rather than filling the article with dozens of citations: